Roche to acquire Swiss antibody-specialist GlycArt
Roche Holding plans to buy GlycArt Biotechnology, a Swiss biotech company that specializes in enhancing the efficacy of antibodies. Roche will pay about CHF 235 million in cash for the outstanding stock of privately held GlycArt, which has three monoclonal 1 antibody drugs in preclinical trials for cancer. Monoclonal antibodies are man-made duplicates of proteins used by the immune system.
- read this story from AFX for more
PLUS: Meanwhile, Roche's first-half net profit declines as sales rise. Story
More stories about pharmaceuticals proteins antibody Cancer biotechnology monoclonal antibodies immune system
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
